Physician profile
Forrest Lyon
NPI 1881254431
$2,330.67
in general payments reported to CMS, 2019-2025
20 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.25 · 2021: $34.25 · 2022: $144 · 2023: $617 · 2024: $776 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.60 | 2023-2025 | |
| Pfizer INC. | $242.77 | 2021-2025 | |
| Lilly USA, LLC | $239.18 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $205.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.57 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $144.61 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $135.17 | 2022-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $132.84 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.55 | 2023-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $108.99 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Mylan Specialty L.P. | $104.49 | 2023-2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $54.15 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $52.80 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $49.11 | 2022-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $31.73 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.13 | 2024 | Quviviq |
| Harmony Biosciences LLC | $28.32 | 2024 | |
| Lundbeck LLC | $26.09 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $16.47 | 2025 | Trintellix |
| Corcept Therapeutics | $16.08 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Lyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.